JP6892381B2 - 多発性骨髄腫を治療するための薬物の組み合わせ - Google Patents

多発性骨髄腫を治療するための薬物の組み合わせ Download PDF

Info

Publication number
JP6892381B2
JP6892381B2 JP2017506390A JP2017506390A JP6892381B2 JP 6892381 B2 JP6892381 B2 JP 6892381B2 JP 2017506390 A JP2017506390 A JP 2017506390A JP 2017506390 A JP2017506390 A JP 2017506390A JP 6892381 B2 JP6892381 B2 JP 6892381B2
Authority
JP
Japan
Prior art keywords
compound
cancer
administered
dose
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017506390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526662A5 (OSRAM
JP2017526662A (ja
Inventor
ダナ ティー． アフタブ，
ダナ ティー． アフタブ，
ピーター ラム，
ピーター ラム，
Original Assignee
エグゼリクシス， インコーポレイテッド
エグゼリクシス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エグゼリクシス， インコーポレイテッド, エグゼリクシス， インコーポレイテッド filed Critical エグゼリクシス， インコーポレイテッド
Publication of JP2017526662A publication Critical patent/JP2017526662A/ja
Publication of JP2017526662A5 publication Critical patent/JP2017526662A5/ja
Application granted granted Critical
Publication of JP6892381B2 publication Critical patent/JP6892381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017506390A 2014-08-05 2015-08-05 多発性骨髄腫を治療するための薬物の組み合わせ Active JP6892381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462033386P 2014-08-05 2014-08-05
US62/033,386 2014-08-05
PCT/US2015/043825 WO2016022697A1 (en) 2014-08-05 2015-08-05 Drug combinations to treat multiple myeloma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019186703A Division JP2020002179A (ja) 2014-08-05 2019-10-10 多発性骨髄腫を治療するための薬物の組み合わせ

Publications (3)

Publication Number Publication Date
JP2017526662A JP2017526662A (ja) 2017-09-14
JP2017526662A5 JP2017526662A5 (OSRAM) 2018-09-06
JP6892381B2 true JP6892381B2 (ja) 2021-06-23

Family

ID=53836256

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017506390A Active JP6892381B2 (ja) 2014-08-05 2015-08-05 多発性骨髄腫を治療するための薬物の組み合わせ
JP2019186703A Pending JP2020002179A (ja) 2014-08-05 2019-10-10 多発性骨髄腫を治療するための薬物の組み合わせ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019186703A Pending JP2020002179A (ja) 2014-08-05 2019-10-10 多発性骨髄腫を治療するための薬物の組み合わせ

Country Status (13)

Country Link
US (1) US11065240B2 (OSRAM)
EP (1) EP3177311B1 (OSRAM)
JP (2) JP6892381B2 (OSRAM)
KR (1) KR102634247B1 (OSRAM)
CN (1) CN106573042A (OSRAM)
AU (1) AU2015301097B2 (OSRAM)
BR (1) BR112017002318A2 (OSRAM)
CA (1) CA2957466C (OSRAM)
EA (1) EA034992B1 (OSRAM)
MA (1) MA40457A (OSRAM)
MX (1) MX382904B (OSRAM)
UA (1) UA121482C2 (OSRAM)
WO (1) WO2016022697A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
US10501418B2 (en) 2014-02-14 2019-12-10 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CA3020749A1 (en) 2016-04-15 2017-10-19 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CA3075714A1 (en) * 2017-09-14 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
EP4647127A3 (en) 2018-01-26 2025-12-17 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
WO2019241504A1 (en) 2018-06-15 2019-12-19 Handa Pharmaceuticals, Llc Kinase inhibitor salts and compositions thereof
WO2023222946A1 (en) 2022-05-18 2023-11-23 Fermion Oy Process for the preparation of cabozantinib
EP4658271A1 (en) 2023-01-31 2025-12-10 Handa Oncology, LLC Improved cabozantinib compositions and methods of use

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6402215B1 (en) * 1996-05-21 2002-06-11 American Moto Products, Inc. Vehicle cargo bed extender
ES2925655T3 (es) 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
AU2005270068B2 (en) 2004-07-02 2012-04-19 Exelixis, Inc. C-Met modulators and method of use
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
TR201900306T4 (tr) 2006-12-14 2019-02-21 Exelixis Inc Mek inhibitörlerini kullanma yöntemleri.
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
TW201022258A (en) 2008-11-13 2010-06-16 Exelixis Inc Methods of preparing quinoline derivatives
WO2010065838A1 (en) 2008-12-04 2010-06-10 Exelixis, Inc. Methods of preparing quinoline derivatives
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
MX2012000809A (es) 2009-07-17 2012-03-14 Exelixis Inc Formas cristalinas de n-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin- 4-ilpropil)oxi]-quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclop ropan-1,1-dicarboxamida.
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
BR112012019302B1 (pt) * 2010-02-03 2022-06-21 Incyte Holdings Corporation Imidazo[1,2-b] [1,2,4]triazinas como inibidores de c-met, composição que as compreende e métodos in vitro de inibir a atividade de c-met cinase, de inibir a via de sinalização da hgf/c-met cinase em uma célula e de inibir a atividade proliferativa de uma célula
TW201202228A (en) 2010-03-12 2012-01-16 Exelixis Inc Hydrated crystalline forms of N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
AU2011278950C1 (en) 2010-07-16 2018-11-22 Exelixis, Inc. c-Met modulator pharmaceutical compositions
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
CA2812753A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EP2621483A1 (en) 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2012064967A2 (en) * 2010-11-10 2012-05-18 Cedars-Sinai Medical Center Cancer cell-derived receptor activator of the nf-kb ligand drives bone and soft tissue metastases
WO2012071321A1 (en) 2010-11-22 2012-05-31 Glaxosmithkline Llc Method of treating cancer
AU2012214322B2 (en) 2011-02-10 2017-04-27 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
US9365516B2 (en) 2011-10-20 2016-06-14 Exelixis, Inc. Process for preparing quinoline derivatives
WO2013070890A1 (en) 2011-11-08 2013-05-16 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
CA2863986A1 (en) * 2012-02-06 2013-08-15 The Regents Of The University Of California Emp2 regulates angiogenesis in cancer cells through induction of vegf
CN103304552B (zh) * 2012-03-09 2016-12-28 广东东阳光药业有限公司 取代的吡啶化合物及其使用方法和用途
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
AU2014248001A1 (en) 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
US10501418B2 (en) 2014-02-14 2019-12-10 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
AR100191A1 (es) 2014-04-25 2016-09-14 Exelixis Inc Método para tratar adenocarcinoma de pulmón
EP3174854B1 (en) 2014-07-31 2022-08-24 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
TW201625243A (zh) 2014-10-14 2016-07-16 艾克塞里克斯公司 用於治療黑素瘤之藥物組合

Also Published As

Publication number Publication date
EP3177311B1 (en) 2024-10-30
EP3177311C0 (en) 2024-10-30
MX382904B (es) 2025-03-13
EA201790312A1 (ru) 2017-06-30
WO2016022697A1 (en) 2016-02-11
JP2020002179A (ja) 2020-01-09
AU2015301097A1 (en) 2017-03-02
EP3177311A1 (en) 2017-06-14
CN106573042A (zh) 2017-04-19
MX2017001490A (es) 2017-05-11
UA121482C2 (uk) 2020-06-10
CA2957466A1 (en) 2016-02-11
KR20170031786A (ko) 2017-03-21
MA40457A (fr) 2017-06-14
AU2015301097B2 (en) 2021-03-04
EA034992B1 (ru) 2020-04-15
KR102634247B1 (ko) 2024-02-05
CA2957466C (en) 2023-10-17
US20170224672A1 (en) 2017-08-10
BR112017002318A2 (pt) 2018-07-17
JP2017526662A (ja) 2017-09-14
US11065240B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
JP6892381B2 (ja) 多発性骨髄腫を治療するための薬物の組み合わせ
TWI812581B (zh) 激酶調節及其適應症
TWI730013B (zh) 用於治療癌症的四環喹諾酮類似物組合療法
AU2011307309A1 (en) Dual inhibitors of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
JP2015536986A (ja) 併用療法
JP2017537899A5 (OSRAM)
AU2011307304A1 (en) Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
JP6768682B2 (ja) メラノーマの処置に使用するためのアピリモド
CN116650500A (zh) 治疗癌症的方法
US9682082B2 (en) Combinations of AKT and MEK inhibitor compounds, and methods of use
KR102490547B1 (ko) 퀴놀린 유도체로 갑상선암을 치료하기 위한 방법과 용도 및 갑상선암을 치료하기 위한 약학적 조성물
JP2019515889A (ja) （１ｓ，４ｓ）−４−（２−（（（３ｓ，４ｒ）−３−フルオロテトラヒドロ−２ｈ−ピラン−４−イル）アミノ）−８−（（２，４，６−トリクロロフェニル）アミノ）−９ｈ−プリン−９−イル）−１−メチルクロロヘキサン−１−カルボキサミドの固体形態及びその使用方法
TW201821080A (zh) 用於治療發炎性疾病之化合物及其醫藥組合物
WO2023031798A1 (en) Dosing regimen for a tead inhibitor
WO2024246824A1 (en) Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
CN117940165A (zh) 利用剪接控制化合物的肿瘤免疫原性的提高
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
EP3515436A1 (en) Combination therapies using indazolylbenzamide derivatives for the treatment of cancer
NZ617508A (en) Method of treating cancer and bone cancer pain
NZ617508B2 (en) Method of treating cancer and bone cancer pain
NZ716805B2 (en) Method of treating cancer and bone cancer pain

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180727

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191010

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200406

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200415

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20200416

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20200626

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20200630

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210114

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20210401

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20210430

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20210430

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210527

R150 Certificate of patent or registration of utility model

Ref document number: 6892381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250